LIVN: Essenz conversions and a differentiated sleep apnea launch underpin multi-year growth ambitions
LivaNova PLC (LIVN) is anticipating multi-year growth driven by Essenz conversions and consumables in cardiopulmonary, and benefits from reimbursement and clinical data in epilepsy. The company plans to launch sleep apnea products in 2027, targeting $200 million-$400 million in revenue by 2030, with expected margin leverage as the business scales. This outlook was based on an audio transcript from the Jefferies Global Healthcare Conference on November 17, 2026.
LivaNova at Jefferies conference: growth plan spans core units and sleep apnea
LivaNova outlined its growth strategy at the Jefferies Global Healthcare Conference, focusing on sustained expansion in its cardiopulmonary and epilepsy businesses, alongside significant investments in new markets like sleep apnea and depression. The company upgraded its full-year growth outlook to 9-10% and detailed a two-phase margin plan, aiming for mid-20s operating margins by 2030 as new ventures scale. Key innovations include a next-generation epilepsy implant, a differentiated sleep apnea treatment, and upgraded cardiopulmonary products.
LivaNova (LIVN) CFO sells shares at $90.91 each under a prearranged trading plan.
LivaNova PLC's Chief Financial Officer, Alex Shvartsburg, sold 2,500 ordinary shares on November 12, 2026, at a price of $90.91 per share. This transaction was executed under a Rule 10b5-1 plan, which was adopted on August 10, 2026. Following the sale, Mr. Shvartsburg directly holds 42,147 ordinary shares in the company.
LivaNova PLC (LIVN) Options Chain - Yahoo Finance
This article provides the options chain data for LivaNova PLC (LIVN) on Yahoo Finance. As of the close on November 12, the stock price was 90.20 USD. The options chain shows no available calls or puts, with data delayed by 15 minutes.
LivaNova PLC (LIVN) Seasonal Returns Chart - Yahoo Finance
The article displays the seasonal returns chart for LivaNova PLC (LIVN) on Yahoo Finance. It shows the average monthly price return for the stock from 2016 to 2026. The current stock price for LIVN is $91.32, up 1.24% as of November 13 at 4:00:01 p.m. EST.
LivaNova's (NASDAQ:LIVN) Strong Earnings Are Of Good Quality
LivaNova PLC (NASDAQ:LIVN) recently reported strong earnings, which the market received positively. Further analysis reveals that the company's statutory profit was reduced by US$405m due to unusual items, which are often one-off in nature, suggesting underlying earnings power may be better. Additionally, LivaNova received a US$77m tax benefit, which temporarily boosted its bottom line but may not be repeatable.
LivaNova PLC (LIA.DU) Seasonal returns chart
The article provides a seasonal returns chart for LivaNova PLC (LIA.DU), showcasing its average monthly price return from 2024 to 2026. It indicates a delayed quote for the company at 81.00 EUR with no change, as of 12:30:18 CET. The page also features navigation to various financial data sections for LivaNova PLC.
LivaNova PLC (LIA.F) Seasonal returns chart
This article provides a seasonal returns chart for LivaNova PLC (LIA.F), showing its average monthly price return from 2016 to 2026. The stock was trading at 81.00 EUR, down 1.22% as of 8:23:23 am GMT+1. The page also includes general market data for various indices, commodities, and currencies.
LivaNova PLC (LIA.DU) Seasonal Returns Chart - Yahoo Finance
This article displays the seasonal returns chart for LivaNova PLC (LIA.DU) on Yahoo Finance, showing the average monthly price return for the period of 2024-2026. As of the delayed quote, the stock is trading at 81.50 EUR, up 1.88%.
LivaNova Raises 2026 Adjusted Diluted EPS Range After 10% Revenue Growth
LivaNova PLC has raised its full-year 2026 revenue growth and adjusted diluted earnings forecasts after reporting a 10% increase in third-quarter revenue to $393.1 million on a constant-currency basis. The medical technology company's revised constant-currency revenue growth target is now 9%-10%, and its adjusted diluted EPS forecast has increased to $4.40-$4.50. The company also announced that its new dedicated oxygenator line has begun operational production, reflecting confidence across its portfolio.
LivaNova Q3 Earnings Call Highlights
LivaNova reported strong third-quarter 2026 revenue growth of 10%, driven by double-digit gains in both its Cardiopulmonary and epilepsy businesses. The company raised its full-year revenue and adjusted earnings outlook, citing robust commercial execution and healthy demand. Key drivers included record placements of the Essenz heart-lung machine, increased oxygenator output, and improved pricing and volumes in the epilepsy segment, alongside ongoing preparations for its obstructive sleep apnea (OSA) technology launch.
Revenue rose 9.9% at LivaNova (LIVN), but operating income fell.
LivaNova PLC reported a 9.9% increase in third-quarter 2026 revenue to $393.148 million, with nine-month revenue rising 11.6% to $1,145.993 million. Despite increased net income, consolidated operating income for the quarter fell to $28.425 million from $54.012 million, largely due to higher litigation provision expenses related to the 3T Heater-Cooler device and increased R&D costs in the Neuromodulation segment. The company also benefited from a $95.0 million discrete Italian tax benefit for the nine-month period.
LivaNova Q3 revenue rises 9.9% to $393.1 million
LivaNova reported a 9.9% increase in Q3 2026 revenue, reaching $393.1 million, driven by growth in its medical technology businesses. The company also raised its full-year 2026 revenue growth guidance to 9%–10% and adjusted EPS guidance to $4.40–$4.50. This performance was supported by strong sales in both cardiopulmonary and neuromodulation segments.
LivaNova plc (LIVN) Tops Q3 EPS by 17c; Offers Guidance
LivaNova plc (LIVN) reported strong third-quarter results, surpassing analyst estimates with an EPS of $1.23, which was $0.17 higher than the consensus. The company also exceeded revenue expectations, bringing in $393.1 million against an estimated $381.1 million. LivaNova provided guidance for FY2026 EPS in the range of $4.40-$4.50, aligning with analyst consensus.
LivaNova (NASDAQ:LIVN): Strong Growth Meets a Technical Breakout Setup
LivaNova (NASDAQ:LIVN) is highlighted as a strong growth stock with a promising technical breakout setup. The company exhibits solid fundamental growth in EPS and revenue, strong profitability, and reasonable valuation, despite some weaknesses in financial health. Technically, LIVN shows positive trends, outperforming peers, and is consolidating near its 52-week highs with a recent pocket pivot signal, suggesting a potential move higher.
How (LIVN) Movements Inform Risk Allocation Models
This article analyzes Livanova Plc (NASDAQ: LIVN) using AI models, indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights a 31.5:1 risk-reward setup, targeting a 9.1% gain with minimal risk. The analysis provides distinct trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
LivaNova PLC (LIA.SG) Seasonal returns chart
This article provides a seasonal returns chart for LivaNova PLC (LIA.SG), detailing its average monthly price return from 2016 to 2026. The stock closed at 70.50 EUR, down 2.76%, on October 30. The page also includes general market data and company-specific financial information.
LivaNova PLC Estimates – NASDAQ:LIVN
This article from TradingView provides an overview of LivaNova PLC (NASDAQ: LIVN) financial estimates. It highlights reported financial data and analyst estimates across various financial statements, allowing users to compare actual results with average, high, and low estimates, and visualize trends over time. The platform offers access to income statements, balance sheets, and cash flow information.
LivaNova Plc Estimates – FWB:LIA
This article provides an overview of LivaNova Plc's financial estimates on the Frankfurt Stock Exchange (FWB:LIA). It highlights where users can explore reported financial data, analyst estimates, and visualize trends across income statements, balance sheets, cash flow, and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates.
LivaNova Plc Estimates – MUN:LIA
This page on TradingView provides financial estimates and actuals for LivaNova Plc (MUN:LIA), a health technology company listed on the Munich Stock Exchange. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics, comparing actual results with average, high, and low estimates. The platform also visualizes trends over time, covering income statements, balance sheets, and cash flow on both annual and quarterly bases.
LivaNova Plc Estimates – GETTEX:LIA
This article provides access to financial actuals and analyst estimates for LivaNova Plc (LIA) on GETTEX, accessible through TradingView. Users can explore reported financial data and analyst estimates across various statements and metrics, compare actual results with estimates, and visualize trends over time. The platform offers detailed views of income statements, balance sheets, and cash flow, available on both annual and quarterly bases.
LivaNova reports 76% seizure reduction in epilepsy study
LivaNova PLC announced 36-month results from its CORE-VNS study, showing a 76% median reduction in seizure frequency among participants with drug-resistant epilepsy. The study, published in Neuromodulation: Technology at the Neural Interface, also reported that 64% of participants achieved at least a 50% seizure reduction, and 16% became completely seizure-free, with no new safety concerns identified.
LivaNova VNS study shows 76% seizure reduction at 36 months
LivaNova's CORE-VNS study, published in Neuromodulation: Technology at the Neural Interface, revealed significant long-term effectiveness of vagus nerve stimulation (VNS) Therapy for drug-resistant epilepsy. The study found a 76% median reduction in seizure frequency at 36 months, with 64% of participants achieving at least a 50% reduction and 16% achieving complete seizure freedom. Additionally, the study reported reduced healthcare resource utilization and improved quality of life, confirming the safety profile of VNS Therapy.
LivaNova PLC (LIVN) Stock forecasts
Argus raised its target price for LivaNova PLC (LIVN) stock to $84.00, citing the company's formation from the combination of Cyberonics and Sorin. The current stock price for LIVN is $81.27. The report, published on October 21, 2026, categorizes LivaNova within the Healthcare sector.
LivaNova PLC (LIA.DU) Analyst Insights, Price Targets & Recommendations
This article provides an overview of analyst insights and ratings for LivaNova PLC (LIA.DU), a company listed on the Dusseldorf stock exchange. It details recent analyst actions, including initiated coverage, reiterations, and maintenance of ratings from firms like Barclays, Piper Sandler, Needham, Mizuho, Freedom Capital Markets, and Keybanc, along with their respective dates. The stock's current price and daily percentage change are also shown.
LivaNova stock trades at EUR 70.00 ahead of November 4 results
LivaNova's stock is trading at EUR 70.00 as the company approaches its third-quarter results release on November 4, 2026. This follows LivaNova's second-quarter revenue increase of 10.80 percent and an uplifted 2026 growth guidance to 8%-9%. Investors will be closely watching the upcoming report to see if demand in its Cardiopulmonary and Neuromodulation businesses continues to support the higher outlook.
Barclays sets USD 105 target and upgrades LivaNova stock
Barclays has upgraded LivaNova (LIVN) stock to "Strong Buy" with a target price of USD 105.00, exceeding its 52-week high. This upgrade follows LivaNova's strong second-quarter 2026 financial performance, which saw a 10.80% revenue increase and an upward revision of its full-year revenue-growth outlook. The company is set to release its third-quarter 2026 results on November 4, 2026, which will test the raised outlook.
Barclays upgraded LivaNova stock to Strong Buy
Barclays has upgraded LivaNova (LIVN) stock to "Strong Buy" on October 8, 2026, ahead of the company's Q3 2026 earnings report scheduled for November 4, 2026. This upgrade follows LivaNova's strong Q2 2026 performance with revenue up 10.80% year over year and a raised full-year revenue growth guidance. The company, trading at EUR 68.00 on October 15, 2026, faces increased investments in capacity and technology, impacting its free cash flow guidance.
(LIVN) Price Dynamics and Execution-Aware Positioning
This article analyzes Livanova Plc (NASDAQ: LIVN) price dynamics, identifying a near-term strong sentiment transitioning to mid-term neutrality and a long-term positive bias. It highlights an exceptional 31.3:1 risk-reward setup with a target gain of 9.2% versus a 0.3% risk. The piece also outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods.
LivaNova PLC (LIVN) Stock Forecasts
Argus has lowered its target price for LivaNova PLC (LIVN) to $79.00. The UK-based company, formed from Cyberonics and Sorin, currently trades at $76.68. The report suggests upgrading for premium research and trade insights.
LivaNova PLC (LIVN) Stock Forecasts
Argus has lowered its target price for LivaNova PLC (LIVN) to $81.00. The company, a UK-based entity formed from the merger of Cyberonics and Sorin, currently has a stock price of $76.38. This report provides a summary of the target price adjustment and general information about LivaNova.
LIVN6033156 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the LivaNova PLC 2.5% 15-MAR-2029 bond (LIVN6033156), covering its key facts, issuer information, and financial specifics. It outlines the bond's issue and maturity dates, face value, and the company's operational segments. The profile also details the interest payment schedule, including the coupon rate, frequency, and upcoming payouts, as well as redemption information.
LivaNova stock stays at USD 3.50 as 52-week range widens
LivaNova stock (LIVN) was quoted at USD 3.50 on September 22, 2026, remaining close to its 50-day moving average of USD 3.52. The 52-week range for the stock is USD 3.10 to USD 4.29, indicating a spread of USD 1.19 or 38.39% of its yearly low. Technical data for the stock on this date showed six sell signals, one neutral signal, and no buy signals.
LivaNova PLC (LIVN) Stock Analysis: A Healthcare Innovator with a 13.98% Upside Potential
LivaNova PLC (LIVN) is a healthcare innovator in medical devices, focusing on Cardiopulmonary and Neuromodulation, with a market cap of $4.31 billion and 10.80% revenue growth. Analysts rate LIVN favorably, with an average target price of $89.10, indicating a 13.98% upside potential. The company shows strong operational efficiency with a 15.40% ROE and $59.87 million in free cash flow, reinvesting for long-term growth rather than paying dividends.
(LIVN) Volatility Zones as Tactical Triggers
This article analyzes Livanova Plc (NASDAQ: LIVN), highlighting a mid-channel oscillation pattern and divergent sentiment across various time horizons. It provides AI-generated trading strategies including a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with multi-timeframe signal analysis indicating weak near-term sentiment but strong long-term prospects. The report also details support and resistance levels for different time horizons.
Director at LivaNova (LIVN) sells 3,500 shares in open-market trade
LivaNova PLC director Francesco Bianchi sold 3,500 Ordinary Shares in an open-market transaction on September 10, 2026, at a weighted-average price of $78.0092 per share, ranging from $77.97 to $78.04. Following this sale, Bianchi directly holds 4,434 shares, and the transaction was not executed under a Rule 10b5-1 trading plan. This insider activity is classified as having a moderate impact and negative sentiment.
LivaNova (NASDAQ: LIVN) Grants 6,291 Derivative Securities to Chief Legal Officer Liddy Anne M.
LivaNova (NASDAQ: LIVN) awarded its Chief Legal Officer, Liddy Anne M., 6,291 derivative securities on September 15, 2026. This transaction represents 100.0% of her total derivative securities holdings post-award. The SEC transaction code for this award is 'A', signifying an acquisition from the company.
Chief legal officer at LivaNova (LIVN) awarded 6,291 stock units vesting through 2029
LivaNova PLC's Chief Legal Officer, Anne M. Liddy, was granted 6,291 Restricted Stock Units (RSUs) on September 15, 2026, under the company's 2022 Incentive Award Plan. These RSUs will vest in tranches over three years, with 20% vesting on March 30, 2027, 40% on March 30, 2028, and the remaining 40% on March 30, 2029, provided vesting conditions are met. Each RSU represents a contingent right to receive one ordinary share of LivaNova PLC and is subject to forfeiture before vesting.
LivaNova Director Francesco Bianchi Disposes 3,500 Shares at $78.01 Each (NASDAQ: LIVN)
LivaNova PLC director Francesco Bianchi sold 3,500 shares of the company at $78.01 per share on September 10, 2026. This transaction reduced his holdings by approximately 44.1%, leaving him with 4,434 shares. The sale details were recorded under code S.
Director at LivaNova (NASDAQ: LIVN) sells 2,300 shares
A director at LivaNova PLC (NASDAQ: LIVN), Story Brooke, sold 2,300 Ordinary Shares of the company on September 4, 2026, for approximately $187,270 at an average price of $81.42 per share. Following this transaction, Brooke directly holds 7,488 Ordinary Shares, and no Rule 10b5-1 trading plan was reported. The sale is considered to have a moderate impact and negative sentiment, according to Rhea-AI.
LivaNova (NASDAQ: LIVN) officer plans 3,500-share sale from 2026 stock award vesting
LivaNova PLC (LIVN) officer Francesco Bianchi plans to sell up to 3,500 shares of common stock, valued at $273,032.19, under Rule 144. These shares originate from a restricted stock unit award that vested on June 15, 2026, as part of the company's equity compensation plan. The filing also notes Bianchi's previous sales of LivaNova common stock during the past three months.
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
LivaNova PLC announced it will present at two September healthcare conferences in New York City: the Morgan Stanley 24th Annual Global Healthcare Conference on September 14th and the Baird 2026 Global Healthcare Conference on September 15th. CEO Vladimir Makatsaria, CFO Alex Shvartsburg, and Chief Strategy Officer Philip Kowalczyk will participate in a fireside chat at Morgan Stanley, with Chief Innovation Officer Ahmet Tezel joining Makatsaria and Shvartsburg at Baird. Webcasts of the discussions will be available for registered attendees and replays will be posted on LivaNova's website.
Piper Sandler raises Livanova stock price target on cardiopulmonary growth outlook
Piper Sandler has increased its price target for Livanova (NASDAQ:LIVN) stock from $87 to $90, maintaining an Overweight rating, based on a positive outlook for the company's cardiopulmonary franchise. This revised target suggests a roughly 9% upside from its current trading price of $82.69. The firm's analysis supports Livanova's long-range plan for mid-to-high single-digit growth in this segment from 2025 to 2030, with InvestingPro Tips indicating expected net income growth and an attractive PEG ratio.
Piper Sandler raises Livanova stock price target on cardiopulmonary growth outlook By Investing.com
Piper Sandler has increased its price target for Livanova stock (NASDAQ:LIVN) to $90 from $87, maintaining an Overweight rating, citing a positive outlook for the company's cardiopulmonary franchise. This adjustment follows a detailed modeling exercise that supports Livanova's long-range plan for mid-to-high single-digit growth in this segment from 2025 to 2030. The firm also noted potential for upside in future years' estimates and highlighted that LivaNova recently surpassed Q2 2026 expectations and raised its full-year guidance.
Is LivaNova (LIVN) Fairly Valued As Growth Hopes Meet Reimbursement Risks?
LivaNova (LIVN) has seen recent investor attention, with its stock closing at $78.74, leading to a market value of approximately $4.34 billion. Despite short-term share price fluctuations, the company shows significant year-to-date and one-year returns, driven by clinical innovations in epilepsy, depression, and obstructive sleep apnea. While analysts view the stock as modestly undervalued with a fair value of $84.80, concerns remain regarding healthcare cost controls, reimbursement scrutiny, and competition.
LIVN Looks 23.4% Overvalued on GF Value™
LivaNova PLC (LIVN) is currently viewed as modestly overvalued by 23.4% according to GuruFocus' GF Value™, despite Mizuho maintaining an Outperform rating due to expected growth in cardiopulmonary and improved epilepsy treatment reimbursements. The company has a strong GF Score™ of 76/100, reflecting solid fundamentals and momentum, but insider activity shows net selling. Investors are advised to consider the valuation alongside growth prospects and insider sentiment.
LivaNova (NASDAQ:LIVN) Downgraded by Zacks Research to "Hold"
Zacks Research has downgraded LivaNova (NASDAQ:LIVN) from a "strong-buy" to a "hold" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $83.50. This downgrade follows LivaNova reporting stronger-than-expected quarterly results, with EPS of $1.26 against an estimated $1.09 and a 10.8% year-over-year revenue increase to $390.59 million. The company's stock opened at $78.21, near its 52-week high, with institutional investors holding a significant 97.64% of outstanding shares.
LivaNova PLC (LIVN) Stock Down 3.3% but Still Overvalued -- GF S
LivaNova PLC (LIVN) shares dropped 3.3% to $78.21, but GuruFocus's GF Value™ still identifies the stock as modestly overvalued, trading 23.4% above its intrinsic value estimate of $63.39. Despite a current P/E ratio significantly lower than its historical median, the GF Score™ of 76/100 highlights strong momentum but weaker profitability and valuation. Insider selling activity further suggests caution for potential investors.
Anne Liddy Joins LivaNova as Chief Legal Officer
LivaNova PLC has appointed Anne Liddy as its new Chief Legal Officer, effective August 31. Liddy brings over two decades of experience in legal, regulatory, M&A, and compliance matters for healthcare and life sciences companies, having previously served as general counsel at Hologic Inc. In her new role, she will oversee LivaNova's global legal and compliance functions and join the executive leadership team, aiming to support the company's strategic priorities and global compliance framework.
LivaNova (NASDAQ:LIVN) Combines Strong Growth With a Promising Technical Breakout Setup
LivaNova (NASDAQ:LIVN) demonstrates strong growth fundamentals with consistent EPS and revenue expansion, coupled with high profitability metrics. The stock also presents a promising technical setup, scoring 10 out of 10 in ChartMill's technical rating, indicating a potential breakout from a resistance zone. This combination of robust growth and a favorable technical chart pattern suggests a potential investment opportunity, though investors should be mindful of the company's health rating and debt ratios.